CN104066743B - 半乳糖凝集素的新型半乳糖苷抑制剂 - Google Patents

半乳糖凝集素的新型半乳糖苷抑制剂 Download PDF

Info

Publication number
CN104066743B
CN104066743B CN201380006432.7A CN201380006432A CN104066743B CN 104066743 B CN104066743 B CN 104066743B CN 201380006432 A CN201380006432 A CN 201380006432A CN 104066743 B CN104066743 B CN 104066743B
Authority
CN
China
Prior art keywords
methyl
bis
galactopyranosyl
sulfane
benzopyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380006432.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104066743A (zh
Inventor
乌尔夫·尼尔松
哈康·莱弗勒
巴拉拉姆·穆克霍帕迪艾
维萨·拉普特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galecto Biotech AB
Original Assignee
Galecto Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galecto Biotech AB filed Critical Galecto Biotech AB
Publication of CN104066743A publication Critical patent/CN104066743A/zh
Application granted granted Critical
Publication of CN104066743B publication Critical patent/CN104066743B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201380006432.7A 2012-01-25 2013-01-24 半乳糖凝集素的新型半乳糖苷抑制剂 Expired - Fee Related CN104066743B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12152413.6A EP2620443A1 (en) 2012-01-25 2012-01-25 Novel galactoside inhibitors of galectins
EP12152413.6 2012-01-25
PCT/EP2013/051339 WO2013110704A1 (en) 2012-01-25 2013-01-24 Novel galactoside inhibitors of galectins

Publications (2)

Publication Number Publication Date
CN104066743A CN104066743A (zh) 2014-09-24
CN104066743B true CN104066743B (zh) 2016-04-06

Family

ID=47598867

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380006432.7A Expired - Fee Related CN104066743B (zh) 2012-01-25 2013-01-24 半乳糖凝集素的新型半乳糖苷抑制剂

Country Status (8)

Country Link
US (1) US9353141B2 (enExample)
EP (2) EP2620443A1 (enExample)
JP (1) JP6158840B2 (enExample)
CN (1) CN104066743B (enExample)
CA (1) CA2854986C (enExample)
ES (1) ES2559857T3 (enExample)
IN (1) IN2014DN05772A (enExample)
WO (1) WO2013110704A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149139A0 (en) 1999-11-03 2002-11-10 Bristol Myers Squibb Co Pharmaceutical compositions containing metformin and glyburide
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
JP6366598B2 (ja) * 2012-11-15 2018-08-01 タフツ ユニバーシティー ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット
US12390486B2 (en) 2012-12-20 2025-08-19 Henry Ford Health System Method for treating diastolic heart failure by inhibiting galectin-3
JP2016507503A (ja) 2012-12-20 2016-03-10 ヘンリー フォード ヘルス システム ガレクチン−３を阻害することによる拡張期心不全を治療する方法
ES2784873T3 (es) * 2014-07-09 2020-10-01 Galecto Biotech Ab Novedoso inhibidor galactósido híbrido de galectinas
CN107406478B (zh) * 2015-01-30 2021-07-27 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
EP3423461A4 (en) * 2016-03-04 2020-03-25 Galectin Sciences, LLC SELENOGALACTOSIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH GALECTIN AND THEIR USE
EP3484903A1 (en) * 2016-07-12 2019-05-22 Galecto Biotech AB Alpha-d-galactoside inhibitors of galectins
WO2018011094A1 (en) * 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CA3062648A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
AU2018395417B2 (en) 2017-12-29 2023-07-13 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
JP2021529163A (ja) 2018-06-29 2021-10-28 グリコス バイオメディカル オーワイ コンジュゲート
WO2020139960A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc Galectin-3 inhibiting c-glycosides
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
US12410208B2 (en) * 2019-08-09 2025-09-09 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-D-galactopyranoside derivatives
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate
CN116270672A (zh) * 2023-02-27 2023-06-23 江苏科技大学 β-D-硫代葡萄糖钠盐在制备缓解或治疗急性肾损伤的药物中的应用
CZ2023132A3 (cs) 2023-04-04 2024-10-16 Ústav Chemických Procesů Av Čr, V. V. I. Komplexy ruthenia pro inhibici galektinů, způsob jejich výroby a jejich použití

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057284A1 (en) * 2001-01-22 2002-07-25 Ulf Nilsson New inhibitors against galectins
WO2005113569A1 (en) * 2004-05-21 2005-12-01 Forskapatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
US20070185039A1 (en) * 2004-05-21 2007-08-09 Ulf Nilsson Novel galactoside inhibitors of galectins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009139719A1 (en) 2008-05-16 2009-11-19 Forskarpatent I Syd Ab Novel synthesis of galactoside inhibitors
US8703720B2 (en) 2009-04-28 2014-04-22 Galecto Biotech Ab Galactoside inhibitors of galectins
WO2014067986A1 (en) 2012-10-31 2014-05-08 Galecto Biotech Ab Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057284A1 (en) * 2001-01-22 2002-07-25 Ulf Nilsson New inhibitors against galectins
WO2005113569A1 (en) * 2004-05-21 2005-12-01 Forskapatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
US20070185039A1 (en) * 2004-05-21 2007-08-09 Ulf Nilsson Novel galactoside inhibitors of galectins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Fluorescence polarization as an analytical tool to evaluate galectin–ligand interactions.;Pernilla, et al.,;《Analytical Biochemistry》;20040825;第334卷(第1期);第36-47页 *

Also Published As

Publication number Publication date
JP2015504909A (ja) 2015-02-16
ES2559857T3 (es) 2016-02-16
JP6158840B2 (ja) 2017-07-05
EP2620443A1 (en) 2013-07-31
US20140336146A1 (en) 2014-11-13
EP2807176B1 (en) 2015-12-30
EP2807176A1 (en) 2014-12-03
IN2014DN05772A (enExample) 2015-04-10
WO2013110704A1 (en) 2013-08-01
CA2854986A1 (en) 2013-08-01
CN104066743A (zh) 2014-09-24
CA2854986C (en) 2019-09-17
US9353141B2 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
CN104066743B (zh) 半乳糖凝集素的新型半乳糖苷抑制剂
KR102626669B1 (ko) 질환의 예방 및 치료를 위한 화합물 및 이의 용도
US8703720B2 (en) Galactoside inhibitors of galectins
US10800804B2 (en) Hybrid galactoside inhibitor of galectins
ES2921500T3 (es) 1,1'-sulfanodiil-di-beta-d-galactopiranósidos como inhibidores de galectinas
ES2865148T3 (es) Ligandos de carbohidratos que se unen a los anticuerpos IgM contra la glucoproteína asociada a mielina
US20070185039A1 (en) Novel galactoside inhibitors of galectins
CN109071585B (zh) 预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途
US9879041B2 (en) Saccharide dendritic cluster compounds as inhibitors of BACE-1
AU2018273411A1 (en) Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160406

Termination date: 20220124

CF01 Termination of patent right due to non-payment of annual fee